Journal
LYMPHATIC RESEARCH AND BIOLOGY
Volume -, Issue -, Pages -Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/lrb.2023.0023
Keywords
venous malformations; Klippel-Trenaunay Syndrome; natural history; prospective observational study; MR volumetry
Categories
Ask authors/readers for more resources
This study followed the clinical course of 34 patients with venous malformation and Klippel-Trenaunay Syndrome for 6 months, evaluating the change in lesion volume and other factors. The results showed that there was no statistically significant difference in lesion volume over the 6 months and no significant changes in other evaluated factors.
Background: The natural history of venous malformation (VM) and Klippel-Trenaunay Syndrome (KTS) has not been quantitatively studied. To obtain benchmarks to guide designing clinical trials to assess safety and efficacy of novel drug candidates, the clinical course of the patients was followed for 6 months.Methods and Results: This is a multicenter prospective observational study evaluating the change rate in lesion volume from baseline with magnetic resonance images, as the primary endpoint. In addition, disease severities, performance status (PS), pain visual analog scale (VAS) score, quality of life (QoL), infections, and coagulation markers were also evaluated. Thirty-four patients (VM = 17, KTS = 17, 1-53 of age; median 15.9 years) with measurable lesion volume were analyzed. There was no statistically significant difference in the lesion volume between baseline and day 180, and the mean change rate (standard deviation) was 1.06 (0.28). There were no baseline characteristics that affected the change in lesion volume over 6 months. However, there were patients who showed more than 20% volume change and it was suggested that the lesion volume was largely impacted by local infection. There were no statistically significant changes in pain VAS score, severity, PS, QoL score, D-dimer, and platelet count over 6 months within all patients analyzed.Conclusion: The results showed the representative natural course of VM and KTS for a 6-month period with objective change of lesion volume and other factors, suggesting that it is scientifically reasonable to conduct a Phase 2 proof-of-concept study without a placebo arm, using the results of this study as the control.Clinical Trial Registration: NCT04285723, NCT04589650.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available